FDA Approves New Drug for Advanced Small Cell Lung Cancer

The FDA has granted approval for ifinatamab deruxtecan, an antibody-drug conjugate, to treat adult patients with extensive-stage small cell lung cancer that has progressed after platinum-based chemotherapy. This decision, following a Priority Review, offers a new therapeutic option for a challenging cancer type, potentially improving outcomes for patients with limited treatment alternatives.